Sitemap
-
News list
- Global Investor Forum Life Science in Maastricht
- ILYA Pharma won the ATTD Startup grant
- ILYA Pharma receives a grant from VINNOVA
- PharmabioticsGlobal 2017
- ILYA Pharma presents at NGM Live tomorrow May 16
- Professor Mia Phillipson in the studio at the presentation of the Nobel Prize Laureates in Physiology or Medicine
- ILYA Pharma wins SweLife Accelerator grant
- Ilya Pharma is awarded three million euros from H2020 EU SME programme
- The innovation and the MOA published by high ranking scientific journal PNAS
- The CEO of Ilya Pharma ranked #20 top entrepreneur in Sweden
- Ilya Pharma in the hot spot
- Female entrepreneurs leading the way
- SwedenBIO Award 2018
- New project manager
- Celebration of safety- and efficacy data from the last preclinical study
- ILYA Pharma will present at the Nordic Life Science Days
- ILYA Pharma is growing and recruiting
- A platform for new biologics and technology innovations
- Ilya Pharma raises additional Euro 3 million to take novel ATMP through to Phase II for wound care
- Ilya Pharma is presenting at "INNOVATIONS IN WOUND HEALING 2018" FL 7-10 dec.
- Ilya Pharma is opening a new indication and recruits a post doctoral scientist with focus on IBD
- Selected top 500 globally of emerging companies in deep tech, Hello Tomorrow challenge
- Evonik 2019
- EIC Investor Day@Nasdaq
- Advanced Wound Care Seminar Redeye in Stockholm
- Hello Tomorrow Investor day
- Ilya Pharma winner at Hello Tomorrow Global Challenge 2019
- Ilya Pharma will present at the 29th Conference of the European Wound Management Association, Gothenburg 5-7 June
- Ilya Pharma will present at Nordic Life Science Days 11-12 September, Malmö
- Ilya Pharma selected to present at Biopharm America/Boston Biotech week 9-12 September
- Ilya Pharma - one of the selected 30 most innovative companies, RESI2019, Boston Biotech Week
- Ilya Pharma will present clinical developments at Bio Investor Forum SF 22-23 October
- Ilya Pharma selected top Innovator and will present at the New England Venture Summit December 4 in Boston
- Ilya Pharma will present new data and development plans for our ILP100 candidate at IBD Innovate, organised by Chrones and Colitis Foundation, NYC 4th of December
- Evelina Vågesjö and the achievements of Ilya Pharma recognised by MIT Tech Review Innovators under 35
- Ilya Pharma selected to present at the IMCAS Congress Innovation Shark Tank in Paris, 31st Jan 2020
- Ilya Pharma will present recent clinical data at Advanced Therapies Congress & Expo 2020 in London March 31
- Ilya Pharma will present developments at SwissNordicBio 6th of February 2020 in Zuric
- Ilya Pharma selected to present at the BIO CEO Investor forum in NYC 10-11th of February.
- Ilya Pharma’s ILP100 Phase I wound care therapy trial progresses swiftly to multiple dosing
- COVID-19
- Operational Report Q1 2020
- Resuming recruitment to the ongoing clinical trial - final cohorts
- Ilya Pharma awarded Euros 5.3 million from EIC Accelerator to fast track Phase II study of first-in-class ILPI100 advanced therapy for wound treatment in people with diabetes
- Ilya Pharma awarded risk-shared funding by EIT Health
- Operational Report Q2 2020
- Meet Margareth Jorvid - leading innovations to products
- Some thoughts from the CEO
- Meet Ingemar Kihlstörm - facilitating the next stage of growth
- Operational Report Q3 2020
- FDA open to new endpoints for patients with difficult wounds
- Latest clinical developments and next raise to be presented at EIC Investor Day 2.0 17-18 December
- Ilya Pharma will present at the Swiss Nordic Bio 10-11 February 2021
- Meet Stefan Roos co-founder and innovator for multiple patents of commercial strains of lactic acid bacteria
- Ilya Pharma extends research collaboration with Uppsala University
- Ilya Pharma presented at the Redeye unlisted event December 2
- Ilya Pharma announces positive results from Phase I trial of lead candidate ILP100 and rapid move to Phase II
- Ilya Pharma approved for funding by the European Innovation Council Equity Fund for high-impact innovation
- Ilya Pharma awarded European patent covering engineered Lactobacillus reuteri strains for use in cutaneous wound therapy
-
Media
- SårMagasinet
- New Swedish technology to cure chronic wounds
- Evelina Vågesjö in UNT
- Uppsala Innovation Center annual report 2014
- Mia Phillipson in Forskarpodden
- The Stockholm-Uppsala Life Science Investment Hotlist
- Evelina Vågesjö in Nya Horisonter
- Professor Mia Phillipson in "Secret lives of cells" from Wallenbergstiftelsen
- SweLife highlights ILYA Pharmas technology and clinical aspirations
- CEO Evelina Vågesjö gives a presentation and an interview at NGM
- ILYA Pharma closes first round of private investment
- Ilya Pharma appoints Ingemar Kihlström as Chairman of the Board
- Uppsala-a good place for Life Science companies
- Research behind ILYA Pharma's innovation featured in science TV programme
- New technology for accelerated wound healing discovered
- BioCentury recognises the clinical importance of the innovative next generation biologis developed by Ilya Pharma
- Our research applauded in Cell Host and Microbe
- Ilya Pharmas technology and vision featured in Manufacturing Chemist
- BioCentury Emerging Company Profile- WOUND-UP BACTERIA
- Ilya Pharma in Microbiome Times
- Ilya Pharma QnA in Biopharma Reporter
- Ilya Pharmas CEO interviewed by the Naked Scientist for BBC Radio
- Professor Mia Phillipson in prestigious scientific podcast describing the immune system and recent advances.
- Ilya Pharma interviewed in seminar of of climate for growth companies in Uppsala County
- Manufacturing Chemist highlights clinical developments of ILP100
- Ilya Pharma interviewed by the real estate company Vasakronan, facilitating growth of companies in Uppsala Science Park
- Ilya Pharmas technology explained in a nice conversation in - Discovery Matters
- Ilya Pharma receives Bio-X grant to complete preclinical work for novel IBD chemokine-based gene therapy candidates
- Four young Nordic life science entrepreneurs wins prestigious award
- Ilya Pharma selected for Springboard’s Health Innovation Hub
- H2020 SME Instrument phase II, WHILYAS-1, successfully completed
- Life Science Sweden recognizes Ilya Pharma
- Ilya Pharma Awarded 5.3 million EUR
- Co-founder of Ilya Pharma shortlisted for pioneering achievements in bringing game-changing innovation to clinical proof of concept.
- First Word Pharma shares news about the first granted US patent for the ILP-technolgy
- Completed recruitment in phase I study for ILP100-Topical published in First Word Pharma
- Immunology week hosted by Swedish TV
- The developments of ILP100 as a new-to-the world drug candidate in cell-and gene therapy featured in Authority Magazine
- Close up with CEO Evelina Vågesjö in Nordic Life Science Magazine #4
- Ilya Pharma extends research collaboration with Uppsala University
- Positive results from Ilya’s Phase I trial
- Firstword Pharma shares news of Ilyas awarded EU patent
- About cookies
- Personer